vida: extract claims from 2026-05-02-cdc-nchs-healthspan-lifespan-gap-2024-widening

- Source: inbox/queue/2026-05-02-cdc-nchs-healthspan-lifespan-gap-2024-widening.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -60,3 +60,10 @@ Qeadan et al. (2025) retrospective cohort study of 1.3M patients across 136 US h
 **Source:** Grigson PS et al., Addiction Science & Clinical Practice 2025
 
 NCT06548490 is the first Phase 2 RCT testing semaglutide for treatment-refractory OUD (n=200, patients already on buprenorphine/methadone who continue illicit use). Trial enrolled first participant January 2025, expected completion November 2026. Protocol formally published in Addiction Science & Clinical Practice (May 2025, PMID 40502777). This represents the definitive human trial that will either confirm or refute the animal/observational signal for OUD, extending the mechanism from AUD to opioid use disorders.
+
+
+## Supporting Evidence
+
+**Source:** Hendershot et al., JAMA Psychiatry 2025
+
+First RCT evidence: 26-week trial of 108 AUD+obesity patients showed semaglutide+CBT reduced heavy drinking days 41.1%, with NNT 4.3 versus 7+ for approved AUD medications. Blood-alcohol biomarkers corroborated self-reports. However, a separate cohort study found 195% increased MDD risk with GLP-1 agonists, requiring psychiatric screening.

domains/health/glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population.md

@@ -0,0 +1,20 @@
+---
+type: claim
+domain: health
+description: "Semaglutide plus CBT reduced heavy drinking days 41.1% in RCT, achieving NNT 4.3 versus 7+ for naltrexone and acamprosate, but limited to AUD patients with obesity comorbidity"
+confidence: experimental
+source: Hendershot et al., JAMA Psychiatry 2025; NIH press release April 2026
+created: 2026-05-02
+title: GLP-1 receptor agonists demonstrate NNT 4.3 for alcohol use disorder in adults with comorbid obesity — superior to all approved AUD medications
+agent: vida
+sourced_from: health/2026-04-xx-nih-jama-psychiatry-glp1-cbt-alcohol-use-disorder-rct.md
+scope: causal
+sourcer: NIH / JAMA Psychiatry
+supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation"]
+challenges: ["the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access"]
+related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression"]
+---
+
+# GLP-1 receptor agonists demonstrate NNT 4.3 for alcohol use disorder in adults with comorbid obesity — superior to all approved AUD medications
+
+A 26-week randomized, double-blind, placebo-controlled trial of 108 patients with both alcohol use disorder and obesity found that weekly semaglutide plus standard cognitive behavioral therapy produced a 41.1% reduction in heavy drinking days, with 13.7% greater improvement than placebo. The number needed to treat (NNT) was 4.3 — meaning approximately 4-5 patients need treatment to prevent one heavy drinking day. This represents a substantial improvement over approved AUD medications: naltrexone and acamprosate have NNTs of 7 or higher. Blood-alcohol biomarkers corroborated self-reported data, addressing a common validity concern in addiction research. The mechanism is hypothesized to involve GLP-1 receptor modulation of mesolimbic dopamine pathways, reducing the hedonic value of alcohol similar to how it reduces food craving. However, this finding is limited to the studied population: adults with comorbid AUD and obesity, which represents approximately 40% of AUD patients. A separate community-based cohort study found 195% increased risk of major depressive disorder among individuals treated with liraglutide or semaglutide, though this observational finding may be confounded by indication (obese/metabolically ill patients have higher baseline depression rates). Phase 3 trials are now underway to determine whether this efficacy translates to broader AUD populations and whether the depression risk signal is causal.

domains/health/us-healthspan-declining-while-lifespan-recovers-creating-divergence.md

@@ -10,12 +10,17 @@ agent: vida
 scope: causal
 sourcer: WHO/JAMA 2024
 related_claims: ["[[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]]", "[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]"]
-supports:
+supports: ["The US has the world's largest healthspan-lifespan gap (12.4 years) despite highest per-capita healthcare spending, indicating structural system failure rather than resource scarcity"]
-- The US has the world's largest healthspan-lifespan gap (12.4 years) despite highest per-capita healthcare spending, indicating structural system failure rather than resource scarcity
+reweave_edges: ["The US has the world's largest healthspan-lifespan gap (12.4 years) despite highest per-capita healthcare spending, indicating structural system failure rather than resource scarcity|supports|2026-04-07"]
-reweave_edges:
+related: ["us-healthspan-declining-while-lifespan-recovers-creating-divergence", "us-healthspan-lifespan-gap-largest-globally-despite-highest-spending"]
-- The US has the world's largest healthspan-lifespan gap (12.4 years) despite highest per-capita healthcare spending, indicating structural system failure rather than resource scarcity|supports|2026-04-07
 ---
 
 # US healthspan declined from 65.3 to 63.9 years (2000-2021) while life expectancy headlines improved, demonstrating that lifespan and healthspan are diverging metrics
 
 WHO data shows US healthspan—years lived without significant disability—actually declined from 65.3 years in 2000 to 63.9 years in 2021, a loss of 1.4 healthy years. This occurred during the same period when life expectancy fluctuated but ultimately reached a record high of 79 years in 2024 according to CDC data. The divergence reveals that headline life expectancy improvements mask a deterioration in the quality of those years. Americans are living longer but spending a greater proportion of their lives sick and disabled. This creates a misleading narrative where public health victories (life expectancy recovery from COVID, opioid crisis improvements) obscure the ongoing failure to maintain functional health. The 12.4-year gap means the average American spends nearly 16% of their life in poor health, and this percentage is growing. For productive capacity and economic output, the relevant metric is healthy years, not total years alive—and by this measure, the US is moving backward despite record healthcare spending.
+
+## Supporting Evidence
+
+**Source:** CDC NCHS Data Brief No. 548 (January 2026), Columbia Public Health healthspan-lifespan gap analysis
+
+CDC/NCHS 2024 data shows US life expectancy recovered to 79.0 years (up 0.6 from 78.4 in 2023), while the healthspan-lifespan gap widened to 12.4 years in 2024 from 10.9 years in 2000 — a 14% worsening. This confirms the divergence pattern: life expectancy is recovering from COVID-era lows while years spent in poor health continue to increase. The gap is now 29% higher than the global mean.

domains/health/us-healthspan-lifespan-gap-largest-globally-despite-highest-spending.md

@@ -10,14 +10,17 @@ agent: vida
 scope: structural
 sourcer: Garmany et al. (Mayo Clinic)
 related_claims: ["[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]", "[[Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated]]"]
-supports:
+supports: ["US healthspan declined from 65.3 to 63.9 years (2000-2021) while life expectancy headlines improved, demonstrating that lifespan and healthspan are diverging metrics", "The US healthcare spending/outcome paradox \u2014 world-class acute care outcomes with dramatically worse preventable mortality \u2014 is the strongest empirical confirmation that non-clinical factors dominate population health"]
-- US healthspan declined from 65.3 to 63.9 years (2000-2021) while life expectancy headlines improved, demonstrating that lifespan and healthspan are diverging metrics
+reweave_edges: ["US healthspan declined from 65.3 to 63.9 years (2000-2021) while life expectancy headlines improved, demonstrating that lifespan and healthspan are diverging metrics|supports|2026-04-07", "The US healthcare spending/outcome paradox \u2014 world-class acute care outcomes with dramatically worse preventable mortality \u2014 is the strongest empirical confirmation that non-clinical factors dominate population health|supports|2026-04-24"]
-- The US healthcare spending/outcome paradox — world-class acute care outcomes with dramatically worse preventable mortality — is the strongest empirical confirmation that non-clinical factors dominate population health
+related: ["us-healthspan-lifespan-gap-largest-globally-despite-highest-spending", "us-healthspan-declining-while-lifespan-recovers-creating-divergence", "us-avoidable-mortality-increased-all-states-while-oecd-declined-with-health-spending-structurally-decoupled-from-outcomes", "us-healthcare-ranks-last-among-peer-nations-despite-highest-spending-because-access-and-equity-failures-override-clinical-quality", "us-healthcare-spending-outcome-paradox-confirms-non-clinical-factors-dominate-population-health"]
-reweave_edges:
-- US healthspan declined from 65.3 to 63.9 years (2000-2021) while life expectancy headlines improved, demonstrating that lifespan and healthspan are diverging metrics|supports|2026-04-07
-- The US healthcare spending/outcome paradox — world-class acute care outcomes with dramatically worse preventable mortality — is the strongest empirical confirmation that non-clinical factors dominate population health|supports|2026-04-24
 ---
 
 # The US has the world's largest healthspan-lifespan gap (12.4 years) despite highest per-capita healthcare spending, indicating structural system failure rather than resource scarcity
 
 The Mayo Clinic study examined healthspan-lifespan gaps across 183 WHO member states from 2000-2019 and found the United States has the largest gap globally at 12.4 years—meaning Americans live on average 12.4 years with significant disability and sickness. This exceeds other high-income nations: Australia (12.1 years), New Zealand (11.8 years), UK (11.3 years), and Norway (11.2 years). The finding is particularly striking because the US has the highest healthcare spending per capita globally, yet produces the worst healthy-to-sick ratio among developed nations. The study found gaps positively associated with burden of noncommunicable diseases and total morbidity, suggesting the US gap reflects structural healthcare system failures in prevention and chronic disease management rather than insufficient resources. This pattern holds even in affluent US populations, ruling out poverty as the primary explanation. The global healthspan-lifespan gap widened from 8.5 years (2000) to 9.6 years (2019), a 13% increase, but the US deterioration is more severe than the global trend.
+
+## Supporting Evidence
+
+**Source:** CDC/NCHS 2024, Columbia Public Health global healthspan analysis
+
+The US healthspan-lifespan gap of 12.4 years is 29% higher than the global mean, with women experiencing a 2.6-year higher gap than men. Only 12% of American adults are metabolically healthy. This confirms the US has the largest healthspan-lifespan gap globally with precise 2024 figures.

inbox/archive/health/2026-04-xx-nih-jama-psychiatry-glp1-cbt-alcohol-use-disorder-rct.md

@@ -7,10 +7,13 @@ date: 2026-04-01
 domain: health
 secondary_domains: []
 format: research-summary
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-02
 priority: high
 tags: [GLP-1, semaglutide, alcohol-use-disorder, behavioral-health, mental-health, clinical-trial, RCT]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2026-05-02-cdc-nchs-healthspan-lifespan-gap-2024-widening.md

@@ -7,10 +7,13 @@ date: 2026-01-01
 domain: health
 secondary_domains: []
 format: government-data
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-02
 priority: high
 tags: [healthspan, life-expectancy, chronic-disease, population-health, CDC, epidemiology, Belief-1]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content